Avadel Pharmaceuticals (Nasdaq:AVDL) - Prezzo delle azioni, notizie e analisi

AVDL Panoramica delle azioni

Avadel Pharmaceuticals plc opera come azienda biofarmaceutica negli Stati Uniti. Maggiori dettagli

AVDL analisi fondamentale
Punteggio fiocco di neve
Valutazione	5/6
Crescita futura	6/6
Prestazioni passate	0/6
Salute finanziaria	4/6
Dividendi	0/6

Premi

Negoziato a 89.4% al di sotto della nostra stima del suo valore equo

Si prevede che gli utili cresceranno del 64.24% all'anno

Gli analisti concordano sul fatto che il prezzo delle azioni salirà di 119.5%

Analisi del rischio

Ha meno di 1 anno di pista di cassa

Avadel Pharmaceuticals plc Concorrenti

CorMedix

NasdaqGM:CRMD

US$671.7m

Phathom Pharmaceuticals

NasdaqGS:PHAT

US$596.9m

scPharmaceuticals

NasdaqGS:SCPH

US$168.1m

Amylyx Pharmaceuticals

NasdaqGS:AMLX

US$355.4m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Avadel Pharmaceuticals
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$10.75
Massimo di 52 settimane	US$19.09
Minimo di 52 settimane	US$10.41
Beta	0
1Variazione di 1 mese	-19.90%
Variazione a 3 mesi	-33.52%
Variazione di 1 anno	n/a
3Variazione a 3 anni	n/a
Variazione a 5 anni	n/a
Variazione dall'IPO	-36.76%

Notizie e aggiornamenti recenti

Avadel Pharmaceuticals plc's (NASDAQ:AVDL) P/S Still Appears To Be Reasonable

Oct 16

Health Check: How Prudently Does Avadel Pharmaceuticals (NASDAQ:AVDL) Use Debt?

Sep 10

Recent updates

Is There An Opportunity With Avadel Pharmaceuticals plc's (NASDAQ:AVDL) 45% Undervaluation?

May 03

Avadel Pharmaceuticals filed for 500M mixed shelf offering

Aug 31

Avadel Pharmaceuticals Q2 2022 Earnings Preview

Aug 08

Avadel Pharmaceuticals (NASDAQ:AVDL) Is Carrying A Fair Bit Of Debt

Jul 07

Avadel rises 18% as it expects tentative approval for sleep disorder drug; expects final approval by June 2023

Jun 29

Avadel: Further Delay, But Some Light At The End Of The Tunnel

Jun 16

Avadel Pharmaceuticals Plc: Initiating Buy, Bye Bye To Sleepiness

Mar 21

Health Check: How Prudently Does Avadel Pharmaceuticals (NASDAQ:AVDL) Use Debt?

Mar 15

Health Check: How Prudently Does Avadel Pharmaceuticals (NASDAQ:AVDL) Use Debt?

Nov 19

Avadel Pharmaceuticals: I Am Holding

Nov 01

Avadel Pharmaceuticals, The Jazz-Killer

Aug 05

Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt In A Risky Way?

Jul 23

Avadel presents new clinical data from Phase 3 REST-ON trial of FT218 in narcolepsy

Jun 09

Avadel Pharmaceuticals EPS beats by $0.09

May 10

Need To Know: The Consensus Just Cut Its Avadel Pharmaceuticals plc (NASDAQ:AVDL) Estimates For 2021

Mar 11

Rendimenti per gli azionisti

	AVDL	US Pharmaceuticals	US Mercato
7D	-10.6%	-3.8%	-1.0%
1Y	n/a	9.8%	30.3%

Ritorno vs Industria: Dati insufficienti per determinare come si è comportato AVDL rispetto al settore US Pharmaceuticals.

Rendimento vs Mercato: Dati insufficienti per determinare la performance di AVDL rispetto al mercato US.

Volatilità dei prezzi

Is AVDL's price volatile compared to industry and market?
AVDL volatility
AVDL Average Weekly Movement	9.4%
Pharmaceuticals Industry Average Movement	9.6%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	3.1%

Prezzo delle azioni stabile: AVDL non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 9% ) di AVDL è rimasta stabile nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2015	154	Greg Divis	www.avadel.com

Avadel Pharmaceuticals plc opera come azienda biofarmaceutica negli Stati Uniti. Il suo prodotto principale è LUMRYZ, una formulazione di sodio ossibato, che è in fase 3 di sperimentazione clinica per il trattamento dell'eccessiva sonnolenza diurna o cataplessia negli adulti affetti da narcolessia. L'azienda, precedentemente nota come Flamel Technologies SA, ha cambiato nome in Avadel Pharmaceuticals plc nel gennaio 2017.

Avadel Pharmaceuticals plc Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Avadel Pharmaceuticals con la sua capitalizzazione di mercato?
AVDL statistiche fondamentali
Capitalizzazione di mercato	US$1.03b
Guadagni(TTM)	-US$72.57m
Ricavi(TTM)	US$138.16m

7.5x

Rapporto P/S

-14.3x

Rapporto P/E

AVDL è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
AVDL Conto economico (TTM)
Ricavi	US$138.16m
Costo del fatturato	US$11.16m
Profitto lordo	US$127.00m
Altre spese	US$199.58m
Guadagni	-US$72.57m

Ultimi guadagni dichiarati

Sep 30, 2024

Prossima data di guadagno

n/a

Utile per azione (EPS)	-0.75
Margine lordo	91.92%
Margine di profitto netto	-52.53%
Rapporto debito/patrimonio netto	48.6%

Come si è comportato AVDL nel lungo periodo?

Vedi performance storica e confronto

AVDL Panoramica delle azioni

Premi

Analisi del rischio

Avadel Pharmaceuticals plc Concorrenti

NasdaqGM:CRMD

US$671.7m

NasdaqGS:PHAT

US$596.9m

NasdaqGS:SCPH

US$168.1m

NasdaqGS:AMLX

US$355.4m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Avadel Pharmaceuticals plc to Report Q3, 2024 Results on Nov 12, 2024

Avadel Pharmaceuticals and nference, Inc. Publish Real-World Data on Narcolepsy in Sleep Advances

Avadel Pharmaceuticals Announces FDA Approval of LUMRYZ (sodium oxybate) Extended-Release Oral Suspension (CIII) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Patients 7 Years of Age and Older with Narcolepsy

Avadel Pharmaceuticals plc's (NASDAQ:AVDL) P/S Still Appears To Be Reasonable

Health Check: How Prudently Does Avadel Pharmaceuticals (NASDAQ:AVDL) Use Debt?

Avadel Pharmaceuticals plc Announces Publication of Restore Data Highlighting Challenges with Twice-Nightly Oxybates and Strong Patient Preference for Once-Nightly LUMRYZ Dosing (sodium Oxybate) Extended-Release Oral Suspension (CIII)

Recent updates

Avadel Pharmaceuticals plc to Report Q3, 2024 Results on Nov 12, 2024

Avadel Pharmaceuticals and nference, Inc. Publish Real-World Data on Narcolepsy in Sleep Advances

Avadel Pharmaceuticals Announces FDA Approval of LUMRYZ (sodium oxybate) Extended-Release Oral Suspension (CIII) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Patients 7 Years of Age and Older with Narcolepsy

Avadel Pharmaceuticals plc's (NASDAQ:AVDL) P/S Still Appears To Be Reasonable

Health Check: How Prudently Does Avadel Pharmaceuticals (NASDAQ:AVDL) Use Debt?

Avadel Pharmaceuticals plc Announces Publication of Restore Data Highlighting Challenges with Twice-Nightly Oxybates and Strong Patient Preference for Once-Nightly LUMRYZ Dosing (sodium Oxybate) Extended-Release Oral Suspension (CIII)

Avadel Pharmaceuticals: The Oxybate War With Jazz Waxes On

Avadel Pharmaceuticals plc Announces Publication in Clinical Therapeutics of Data Highlighting Weight Loss in People with Narcolepsy Treated with LUMRYZ™ (sodium oxybate) Extended-Release Oral Suspension

Avadel Pharmaceuticals plc to Report Q2, 2024 Results on Aug 08, 2024

Avadel Pharmaceuticals plc Announces First Patient Dosed in Phase 3 REVITALYZ Trial of LUMRYZ (sodium oxybate) Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

Avadel Pharmaceuticals plc, Annual General Meeting, Jul 30, 2024

Avadel Pharmaceuticals plc, Annual General Meeting, Jul 30, 2024

Avadel Pharmaceuticals: Inflection Point Ahead

Avadel Pharmaceuticals plc Appoints Naseem Amin to Its Board of Directors

Avadel Pharmaceuticals Shares New LUMRYZ (sodium Oxybate) for Extended-Release Oral Suspension (CIII) Data at Sleep 2024

Avadel Pharmaceuticals plc Appoints Naseem Amin to Its Board of Directors

Avadel Pharmaceuticals plc has completed a Follow-on Equity Offering.

Avadel Pharmaceuticals plc has filed a Follow-on Equity Offering in the amount of $100 million.

Avadel Pharmaceuticals plc to Report Q1, 2024 Results on May 08, 2024

New major risk - Share price stability

Avadel Pharmaceuticals: A Deep Dive Into Lumryz's Once-Nightly Revolution

Price target increased by 8.0% to US$22.90

Avadel Pharmaceuticals: Robust Launch Of Lumryz And Eased Litigation Overhang

Avadel Pharmaceuticals: Strong Launch Of Lumryz With A Legal Risk Backdrop

Is Avadel Pharmaceuticals (NASDAQ:AVDL) Weighed On By Its Debt Load?

Avadel May Continue To Outperform With Positive Launch Momentum

Avadel Pharmaceuticals plc to Report Fiscal Year 2023 Results on Feb 29, 2024

Independent Director recently sold US$1.1m worth of stock

Independent Director notifies of intention to sell stock

Consensus revenue estimates increase by 18%, EPS downgraded

Avadel Pharmaceuticals Announces Data Supporting Clinical Profile for Lumryz (Sodium Oxybate) for Extended-Release Oral Suspension (Ciii) At World Sleep 2023

Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt Sensibly?

New minor risk - Insider selling

Consensus EPS estimates fall by 54%, revenue upgraded

Key Executive recently bought US$188k worth of stock

Avadel Pharmaceuticals plc to Report Q2, 2023 Results on Aug 09, 2023

Are Investors Undervaluing Avadel Pharmaceuticals plc (NASDAQ:AVDL) By 49%?

Price target increased by 7.1% to US$19.33

Consensus EPS estimates upgraded to US$1.28 loss

Avadel Pharmaceuticals plc Announces Publication of Study Data in Advances in Therapy Highlighting Need for Once-At-Bedtime Oxybate Dosing for Narcolepsy

Price target increased by 9.8% to US$18.06

Avadel Pharmaceuticals plc Announces U.S. Commercial Launch of LUMRYZ for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Adults Living with Narcolepsy

Avadel Pharmaceuticals plc Announces Data Supporting Clinical Profile for LUMRYZ™ at SLEEP 2023

Independent Director recently bought US$181k worth of stock

Consensus revenue estimates increase by 17%

Is There An Opportunity With Avadel Pharmaceuticals plc's (NASDAQ:AVDL) 45% Undervaluation?

Price target increased by 20% to US$15.85

Consensus revenue estimates fall by 15%

Consensus revenue estimates increase by 15%, EPS downgraded

Avadel Pharmaceuticals plc Announces Publication of Real-World Data Describing Risk of Accidental Dosing Errors with Immediate-Release Twice-Nightly Oxybate

Insufficient new directors

Price target increased to US$12.25

Independent Director recently bought US$156k worth of stock

Avadel Pharmaceuticals Presents New Real-World Data Describing Demographic Characteristics and Comorbidities of Patients with Narcolepsy at ANA 2022

Avadel Pharmaceuticals filed for 500M mixed shelf offering

Price target increased to US$10.95

Avadel Pharmaceuticals Q2 2022 Earnings Preview

Price target increased to US$10.10

Avadel Pharmaceuticals plc Announces Tentative Approval of LUMRYZ Extended-Release Oral Suspension